Viral Vector-Based Techniques for Optogenetic Modulation In Vivo - Viral Vector Approaches in Neurobiology and Brain Diseases - page 298

7. Zhang F et al (2011) The microbial opsin
family of optogenetic tools. Cell 147:
1446-1457
8. Zhang F et al (2007) Multimodal fast optical
interrogation of neural circuitry. Nature
446:633-642
9. Chow BY et al (2010) High-performance
genetically targetable optical neural silencing by
light-driven proton pumps. Nature 463: 98-102
10. Yizhar O, Fenno LE, Davidson TJ, Mogri M,
Deisseroth K (2011) Optogenetics in neural
systems. Neuron 71:9-34
11. Fenno L, Yizhar O, Deisseroth K (2011) The
development and application of optogenetics.
Annu Rev Neurosci 34:389-412
12. Kravitz AV, Kreitzer AC (2011) Optogenetic
manipulation of neural circuitry in vivo. Curr
Opin Neurobiol 21:433-439, available at http://
www.ncbi.nlm.nih.gov/pubmed/21420852

23. Nathanson JL, Yanagawa Y, Obata K, Callaway
EM (2009) Preferential labeling of inhibitory
and excitatory cortical neurons by endogenous
tropism of adeno-associated virus and lentivi-
rus vectors. Neuroscience 161:441-450
24. Adamantidis AR, Zhang F, Aravanis AM,
Deisseroth K, de Lecea L (2007) Neural sub-
strates of awakening probed with optogenetic
control of hypocretin neurons. Nature
450:420-424
25. Benzekhroufa K, Liu B-H, Teschemacher AG,
Kasparov S (2009) Targeting central seroto-
nergic neurons with lentiviral vectors based on
a transcriptional amplifi cation strategy. Gene
Ther 16:681-688
26. Gradinaru V et al (2010) Molecular and cel-
lular approaches for diversifying and extending
optogenetics. Cell 141:154-165
27. Aravanis AM et al (2007) An optical neural
interface: in vivo control of rodent motor cor-
tex with integrated fi beroptic and optogenetic
technology. J Neural Eng 4:S143-S156
28. Gradinaru V, Mogri M, Thompson KR,
Henderson JM, Deisseroth K (2009) Optical
deconstruction of parkinsonian neural cir-
cuitry. Science 324:354-359
29. Berndt A, Yizhar O, Gunaydin LA, Hegemann
P, Deisseroth K (2009) Bi-stable neural state
switches. Nat Neurosci 12:229-234
30. Yizhar O et al (2011) Neocortical excitation/
inhibition balance in information processing
and social dysfunction. Nature 477:171-178
31. Grimm D, Kay MA (2003) From virus evolu-
tion to vector revolution: use of naturally
occurring serotypes of adeno-associated virus
(AAV) as novel vectors for human gene ther-
apy. Curr Gene Ther 3:281-304
32. Duque S et al (2009) Intravenous administra-
tion of self-complementary AAV9 enables
transgene delivery to adult motor neurons.
Mol Ther 17:1187-1196
33. Foust K et al (2009) Intravascular AAV9 pref-
erentially targets neonatal neurons and adult
astrocytes. Nat Biotechnol 27:59-65
34. Dayton R, Wang D, Klein R (2012) The
advent of AAV9 expands applications for brain
and spinal cord gene delivery. Expert Opin
Biol Ther 12:757-766
35. Cearley CN, Wolfe JH (2007) A single injec-
tion of an adeno-associated virus vector into
nuclei with divergent connections results in
widespread vector distribution in the brain and
global correction of a neurogenetic disease.
J Neurosci 27:9928-9940
36. Raghavan R et al (2006) Convection-enhanced
delivery of therapeutics for brain disease, and
its optimization. Neurosurg Focus 20:E12.
doi: 10.3171/foc.2006.20.4.7
37. Mastakov M, Baer K, Xu R, Fitzsimons H,
During M (2001) Combined injection of

13. Mattis J et al (2011) Principles for applying
optogenetic tools derived from direct compar-
ative analysis of microbial opsins. Nat Methods
9:159-172
14. Dittgen T et al (2004) Lentivirus-based genetic
manipulations of cortical neurons and their opti-
cal and electrophysiological monitoring in vivo.
Proc Natl Acad Sci USA 101:18206-18211
15. Monahan PE, Samulski RJ (2000) Adeno-
associated virus vectors for gene therapy: more
pros than cons? Mol Med Today 6:433-440
16. Nathanson JL et al (2009) Short promoters in
viral vectors drive selective expression in mam-
malian inhibitory neurons, but do not restrict
activity to specifi c inhibitory cell-types. Front
Neural Circuits 3:19
17. Knobloch HS et al (2012) Evoked axonal oxy-
tocin release in the central amygdala attenuates
fear response. Neuron 73:553-566
18. Burger C et al (2004) Recombinant AAV viral
vectors pseudotyped with viral capsids from
serotypes 1, 2, and 5 display differential effi -
ciency and cell tropism after delivery to differ-
ent regions of the central nervous system. Mol
Ther 10:302-317
19. Kato S et al (2011) Neuron-specifi c gene
transfer through retrograde transport of lenti-
viral vector pseudotyped with a novel type of
fusion envelope glycoprotein. Hum Gene
Ther 22:1511-1523
20. Sohal VS, Zhang F, Yizhar O, Deisseroth K
(2009) Parvalbumin neurons and gamma
rhythms enhance cortical circuit performance.
Nature 459:698-702
21. Tsai H-C et al (2009) Phasic fi ring in dopami-
nergic neurons is suffi cient for behavioral con-
ditioning. Science 324:1080-1084
22. Zolotukhin S et al (2002) Production and
purifi cation of serotype 1, 2, and 5 recombi-
nant adeno-associated viral vectors. Methods
28:158-167